Yarrow Bioscience (YARW) Other Non-Current Assets (2016 - 2025)
Yarrow Bioscience's (YARW) quarterly Other Non-Current Assets came in at $60000.0 in Q4 2025, down 97.35% YoY from $2.3 million in Q4 2024, and down 75.1% on a QoQ basis from $241000.0 in Q2 2025.
Yarrow Bioscience (YARW) Other Non-Current Assets (2016 - 2025) Analysis & Trends
Yarrow Bioscience (YARW) has 9 years of Other Non-Current Assets data on file, last reported at $60000.0 in Q4 2025.
- Quarterly Other Non-Current Assets fell 97.35% year-over-year to $60000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $60000.0 (down 97.35% YoY) and the FY2025 annual result came in at $60000.0, down 97.35% from the prior year.
- Other Non-Current Assets declined to $60000.0 in Q4 2025, from $241000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $4.1 million in Q1 2021 to a low of $60000.0 in Q4 2025.
- A 5-year average of $2.1 million and a median of $2.3 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 1415.0% — and 2025, when it tumbled 97.35%.
- Tracing YARW's Other Non-Current Assets over 5 years: stood at $3.5 million in 2021, then tumbled by 97.15% to $100000.0 in 2022, then jumped by 1415.0% to $1.5 million in 2023, then jumped by 49.31% to $2.3 million in 2024, then plunged by 97.35% to $60000.0 in 2025.
- The last three Other Non-Current Assets figures came in at $60000.0 (Q4 2025), $241000.0 (Q2 2025), and $1.3 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 60,000.00 |
| Jun 30, 2025 | 241,000.00 |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 2.26 Mn |
| Sep 30, 2024 | 2.54 Mn |
| Jun 30, 2024 | 2.72 Mn |
| Mar 31, 2024 | 1.27 Mn |
| Dec 31, 2023 | 1.52 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 100,000.00 |
| Sep 30, 2022 | 2.74 Mn |
| Jun 30, 2022 | 2.97 Mn |
| Mar 31, 2022 | 3.36 Mn |
| Dec 31, 2021 | 3.51 Mn |
| Sep 30, 2021 | 3.68 Mn |
| Jun 30, 2021 | 3.83 Mn |
| Mar 31, 2021 | 4.12 Mn |
| Dec 31, 2020 | 4.35 Mn |